Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis

A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 132 participants.

Also called NCT01104311

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 132 participants (enrolled count) (from the registry)
Sponsor
  • Asan Medical Center Registry lists this organization as the lead sponsor
  • Pfizer Registry lists this organization as a collaborator
Registry
  • NCT NCT01104311
Other papers using this trial's data
  • Intensive blood pressure control may not be safe in subacute ischemic stroke by intracranial atherosclerosis: a result of randomized trial Journal of hypertension, 2018-09 DOI, PubMed 29847486

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
South Korea (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT01104311. Randomized; single masking; primary purpose treatment. Start 2010-04 (registry gives no type); primary completion 2014-04 (actual). Results posted on 2017-03-07.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis
Acronym
STABLE-ICAS
Condition
Brain Ischemia
Intervention (Procedure)
Aggressive BP lowering
Intervention (Procedure)
modest blood pressure lowering
Lead sponsor
Asan Medical Center (class: other)
Collaborator
Pfizer (class: industry)

Record details

Record id
cardio:ct-nct01104311
Content hash
7b5cea4307404b67966b1665ca6542d6b3e047853f67bbbee2cc5dbe6b198e11